This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS

Feasibility of reirradiation in the treatment of locally recurrent rectal cancer. BJS 2014; 101: 1280-1289.

Published: 22nd July 2014

Authors: S. J. Bosman, F. A. Holman, G. A. P. Nieuwenhuijzen, H. Martijn, G.‐J. Creemers, H. J. T. Rutten et al.

Background

Many patients with locally recurrent rectal cancer receive radiotherapy for the treatment of the primary tumour. It is unclear whether reirradiation is safe and effective when a local recurrence develops. The aim of this study was to evaluate the toxicity and oncological outcome of reirradiation in patients with locally recurrent rectal carcinoma.

Method

From March 1994 until December 2013, data on patients with locally recurrent rectal cancer (without distant metastasis) were entered into a database. Patients were reirradiated with a reduced dose of 30 Gy and received an intraoperative electron radiotherapy boost during surgery. Morbidity associated with radiotherapy, postoperative complications and oncological outcome were evaluated.

Results

Clear margins (R0) were obtained in 75 (55·6 per cent) of the 135 patients who were reirradiated. Forty‐six patients developed serious postoperative complications and the 30‐day mortality rate was 4·6 per cent. Multivariable analysis showed that margin status was the main factor influencing oncological outcome (hazard ratio for overall survival 2·51 for R1 and 3·19 for R2 versus R0 resection; both P < 0·001). There was no significant difference in survival between the reirradiated group and a group of 113 patients who had full‐course irradiation (5‐year overall survival rate 34·1 and 39·1 per cent respectively; P = 0·278). Both reirradiation and full‐course irradiation were associated with better survival than no irradiation in a historical control group of 24 patients (5‐year overall survival rate 23 per cent; P = 0·225 and P = 0·062).

Conclusion

Reirradiation (with concomitant chemotherapy) has few side‐effects and complements radical resection of recurrent rectal cancer.

Full text

You may also be interested in

Original article

Early MRI predictors of disease‐free survival in locally advanced rectal cancer from the GRECCAR 4 trial. BJS 2019; 106: 1530-1541.

Authors: S. Nougaret, F. Castan, H. Forges, H. A. Vargas, B. Gallix, S. Gourgou et al.

Original article

Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial.

Authors: B. Garlipp, P. Gibbs, G. A. Van Hazel, R. Jeyarajah, R. C. G. Martin, C. J. Bruns et al.

Original article

Population‐based study of the impact of small bowel obstruction due to adhesions on short‐ and medium‐term mortality.

Authors: R. Behman, A. B. Nathens, B. Haas, N. Look Hong, P. Pechlivanoglou, P. Karanicolas et al.

Original article

Prospective cohort study of appendicectomy for treatment of therapy‐refractory ulcerative colitis.

Authors: M. E. Stellingwerf, S. Sahami, D. C. Winter, S. T. Martin, G. R. D'Haens, G. Cullen et al.

Original article

Long‐term follow‐up of the AVOD randomized trial of antibiotic avoidance in uncomplicated diverticulitis. BJS 2019; 106: 1542-1548.

Authors: D. Isacson, K. Smedh, M. Nikberg, A. Chabok

Original article

Pushing the boundaries of pelvic exenteration by maintaining survival at the cost of morbidity. BJS 2019; 106: 1393-1403.

Authors: R. L. Venchiarutti, M. J. Solomon, C. E. Koh, J. M. Young, D. Steffens

Systematic review

Meta‐analysis of the role of colonoscopy after an episode of left‐sided acute diverticulitis. BJS 2019; 106: 988-997.

Authors: S. J. Rottier, S. T. Dijk, A. A. W. Geloven, W. H. Schreurs, W. A. Draaisma, W. A. Enst et al.

Randomized clinical trial

Multicentre randomized clinical trial of colonic J pouch or straight stapled colorectal reconstruction after low anterior resection for rectal cancer.

Authors: S. Pucciarelli, P. Del Bianco, U. Pace, F. Bianco, A. Restivo, I. Maretto et al.

Review

Mechanisms of immunogenicity in colorectal cancer. BJS 2019; 106: 1283-1297.

Authors: T. O. Sillo, A. D. Beggs, D. G. Morton, G. Middleton

Systematic review

Meta‐analysis of the effect of extending the interval after long‐course chemoradiotherapy before surgery in locally advanced rectal cancer. BJS 2019; 106: 1298-1310.

Authors: É. J. Ryan, D. P. O'Sullivan, M. E. Kelly, A. Z. Syed, P. C. Neary, P. R. O'Connell et al.

Randomized clinical trial

Randomized clinical trial of accelerated enhanced recovery after minimally invasive colorectal cancer surgery (RecoverMI trial). BJS 2019; 106: 1311-1318.

Authors: B. K. Bednarski, T. P. Nickerson, Y. N. You, C. A. Messick, B. Speer, V. Gottumukkala et al.

Original article

Postoperative complications in relation to overall treatment time in patients with rectal cancer receiving neoadjuvant radiotherapy.

Authors: J. Erlandsson, D. Pettersson, B. Glimelius, T. Holm, A. Martling